Global pharmaceutical company Lupin Limited has entered into a strategic collaboration with LABORATORIOS ERN SA to introduce Luforbec®, a fixed-dose combination therapy for asthma and chronic obstructive pulmonary disease (COPD), in Spain.
The agreement marks an important step in expanding access to respiratory treatments in one of Europe’s key healthcare markets. It combines Lupin’s expertise in respiratory medicine and inhalation technologies with ERN’s established commercial network and strong relationships within Spain’s healthcare sector.
Luforbec® contains a combination of beclometasone and formoterol delivered through a pressurized metered-dose inhaler (pMDI). The therapy is designed for adult patients requiring long-term management of asthma and COPD, two chronic respiratory conditions that affect millions of people worldwide and place a significant burden on healthcare systems.
The launch follows successful introductions of the product in other major European markets, including the United Kingdom and Germany. By extending availability to Spain, the collaboration aims to provide healthcare professionals with an additional treatment option while supporting better disease management and patient outcomes.
Respiratory diseases remain among the leading causes of chronic illness globally, driving demand for effective and reliable inhalation therapies. Advances in treatment technologies and growing awareness of disease management have increased the importance of ensuring broad access to quality respiratory medicines.
Lupin views the partnership as part of its broader strategy to strengthen its presence in international respiratory markets. The company has built significant capabilities in the development and manufacture of inhalation products and continues to expand its portfolio across multiple therapeutic areas.
For ERN, the collaboration represents an opportunity to enter the respiratory care segment while leveraging its extensive market experience and nationwide reach. The company has established a strong reputation within Spain’s pharmaceutical industry and brings deep knowledge of local healthcare systems, medical professionals and patient needs.
Executives from both organizations highlighted the strategic importance of the agreement and its potential to enhance respiratory care options for patients across Spain. By combining complementary strengths, the companies aim to support healthcare providers with proven therapies backed by strong scientific and manufacturing expertise.
Lupin continues to maintain a significant global presence across branded and generic pharmaceuticals, biotechnology products, active pharmaceutical ingredients, and specialty medicines. Headquartered in Mumbai, the company markets its products in more than 100 countries and has built strong positions across multiple therapeutic categories, including respiratory care, cardiovascular medicine, diabetes management, anti-infectives, gastroenterology, central nervous system disorders, and women’s health.
Supported by an extensive manufacturing and research network, Lupin operates multiple production facilities and research centers worldwide. The company’s activities also extend into diagnostics, digital health solutions, and pharmaceutical manufacturing services through its specialized business divisions.
